TAK-062

Phase 2Small molecule

Takeda

TAK-062 is one of 35 small molecule programs targeting Celiac Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Celiac DiseaseActive, not recruiting

Celiac DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Celiac Disease

#DrugCompanyPhaseTrials

VIOKACE

DDigestive Care, Inc.

Approved

1 2

Tylenol

KKenvue Brands

Approved

1 3

Advil

KKenvue Brands

Approved

1 4

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

—5

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Ferinject

1 7

Iron

WWatson Pharmaceuticals

Approved

1 8

Zocor

OOrganon and Co

Phase 3

1 9

Opzelura

Pfizer

Phase 2

1 10

Entyvio

Takeda

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Celiac Disease1 trial

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Completed· Takeda logo

Takeda·Phase 2·NCT05353985·153 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TAK-062. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-062 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-062. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Takeda

TAK-062

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Celiac Disease1 trial

References

Drug Info

Quick Facts

Related News